Stocklytics score rationale: value 30, quality 49, growth 63.
Financials
2023
2024
2025
0
0
0
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss…
Forecast
Consensus Buy from 7 analysts. Average price target $174.00, +19.8% versus the current price. Low $136.00. High $204.00.
Analysts have an average 12-month price target of $174.00 for Veradermics (MANE), 19.8% above the current price of $145.25. Of 7 analysts covering the stock, 7 rate it Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
MANE price target
12-month price target
Low
$136.00
Average
$174.00
High
$204.00
The average is 19.8% above the current price of $145.25.
Is Veradermics a buy or sell?
Of 7 analysts, 7 rate Veradermics Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
The Stocklytics Score for MANE is 47 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
MANE forecast FAQs
What is the MANE price target?
$174.00 average, with a published range of $136.00 to $204.00.
Is Veradermics a buy or sell?
The consensus is Buy from 7 analysts. This is not a recommendation.
What is the Veradermics stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is -2.82. The average revenue estimate is $0.
What will MANE be worth in 2030?
No reliable forecast exists that far out.
When is Veradermics's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.